| Document |
Document Title |
|
WO/2020/209059A1 |
This disclosure provides a pharmaceutical composition for treating hyperammonemia that contains α-ketoglutaric acid or dimethyl-α-ketoglutaric acid, or a pharmaceutically acceptable salt thereof.
|
|
WO/2020/207611A1 |
The invention concerns a compound of Formula (I) or a pharmaceutically acceptable salt or derivative thereof, wherein R1 and R2 are independently H or a group -O(CHR5)nR6, where n is an integer value from 1 to 3, R5 is independently H or...
|
|
WO/2020/210626A1 |
Disclosed are spray-dried formulations of 4-chloro-5-(4-(4-fluoro-2- (trifluoromethyl)phenoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-
7(6H)-yl)pyridazin-3(2H)-one, methods and compositions for making the same, and solid dosage forms comprisi...
|
|
WO/2020/210628A1 |
Compositions and methods are provided that enhance the ability of low- or non-responding individuals undergoing renal replacement therapy to develop a protective antibody response following immunization. A toll-like receptor agonist is a...
|
|
WO/2020/210597A1 |
The present invention provides compounds which inhibit the activity of TRPC6, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the inve...
|
|
WO/2020/206623A1 |
Disclosed are crystalline forms of Compound 100. In one embodiment, a crystalline form of Compound 100 has characteristic peaks in the XRPD pattern as shown in any one of Figures 1A, 2A, 3A, and 4A.
|
|
WO/2020/209636A1 |
The present invention relates to a method for inducing direct reprogramming of urine cells into renal progenitor cells and a pharmaceutical composition comprising the renal progenitor cells reprogrammed by the method for preventing or tr...
|
|
WO/2020/210639A1 |
The invention relates to crystalline forms of Compound (100), pharmaceutical compositions comprising the same and methods of treatment using the same. Compound (100) is a TRPC1, TRPC4 and TRPC5 ion channels inhibitor useful for treating ...
|
|
WO/2020/204624A1 |
The present invention provides a novel prodrug of a mirabegron compound or pharmaceutically acceptable salts thereof, a pharmaceutical composition comprising same as an active ingredient, and a pharmaceutical use of same for treating or ...
|
|
WO/2020/201833A1 |
Disclosed are methods and compounds for use for treating urinary tract infection comprising administering gepotidacin or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount in a human In need thereof, wherei...
|
|
WO/2020/204848A1 |
Maltodextrin has been added to the aqueous extracts prepared from the capitula of the Helichrysum stoechas and removed the water by spray drying. The dried extract was standardized and tablets, capsules and sachet formulations were prepa...
|
|
WO/2020/202601A1 |
[Problem] The present invention addresses the problem of searching for and providing a novel acetylcholinesterase inhibitor. [Solution] The present invention provides an acetylcholinesterase inhibitor containing wood-tar creosote as an...
|
|
WO/2020/205921A1 |
Compounds which are thiazole and triazole derivatives are disclosed, including compounds of the following genus: Formula I. The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative ...
|
|
WO/2020/205501A1 |
The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compoun...
|
|
WO/2020/206299A1 |
The disclosure is directed to methods of treatment using compounds of Formula (I).
|
|
WO/2020/206289A1 |
The disclosure is directed to methods of treating disease using compounds of Formula (I).
|
|
WO/2020/205523A1 |
Antibody molecules that specifically bind to FGF23 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as FGF23-associated disorders.
|
|
WO/2020/198166A1 |
Materials and methods for treating polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease (ADPKD)) are provided herein that include using one or more inhibitors of pregnancy associated plasma protein A (PAPP-A) pol...
|
|
WO/2020/194209A1 |
Described herein are compounds of Formula (I) that are inhibitors of mTORC1, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
|
|
WO/2020/191501A1 |
Methods and uses of bemithyl and derivatives of the formula (I) for treating fibrotic diseases are taught, and in particular, chronic lung disease, including idiopathic pulmonary fibrosis; non-alcoholic fatty liver disease, and in partic...
|
|
WO/2020/191503A1 |
Methods and uses of bromantane and derivatives of the Formula (Ia) or (Ib) for treating fibrotic diseases are taught, and in particular, chronic lung disease, including idiopathic pulmonary fibrosis; non-alcoholic fatty liver disease, an...
|
|
WO/2020/194563A1 |
The purpose of the present invention is to provide a substance which has the action of reducing phenols and which has the action of preventing or improving symptoms or disease caused by phenols. Because administration of the compound s...
|
|
WO/2020/195037A1 |
Problem: To provide a pharmaceutical composition for prevention or treatment of urinary track organ cancer. The composition does not cause a problem with respect to side effects, can be continually used for an extended period of time, an...
|
|
WO/2020/196816A1 |
A means for reducing side effects of tolvaptan is provided. Specifically, the means provides a pharmaceutical composition comprising a compound represented by Formula (1) or a metal salt thereof, wherein the pharmaceutical composition is...
|
|
WO/2020/193652A1 |
The present disclosure provides methods for treating chronic kidney disease, comprising administering to a patient in need thereof, a therapeutically effective amount of canagliflozin; wherein the patient is diagnosed with Type II diabet...
|
|
WO/2020/194531A1 |
The present invention addresses the problem of providing a substance that has: an effect of effectively reducing (decreasing) the amount of a uremic substance present in the blood; an effect of effectively preventing or ameliorating urem...
|
|
WO/2020/196946A1 |
One aspect of the present disclosure relates to a novel long-acting fatty acid-binding gonadotrophin-releasing hormone (GnRH) derivative of GnRH and a pharmaceutical composition comprising same. The present disclosure is expected to grea...
|
|
WO/2020/191502A1 |
Emoxypine, and derivatives of Emoxypine, are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject. Emoxypine, and derivatives of Emoxypine, are also used for the treatment or pro...
|
|
WO/2020/187718A1 |
The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibo...
|
|
WO/2020/188457A1 |
Pharmaceutical compositions comprising a vehicle, a solubilizer, and a surfactant are disclosed to be used in conjunction with non-chemotherapeutic active pharmaceutical ingredients which are soluble in water but subject to hydrolysis to...
|
|
WO/2020/188564A1 |
Provided herein are prognostic and treatment methods for prostate cancer. The level of an of miR-451, miR-106a, and miR-182 is detected and compared with a threshold level of the detected miRNA, which determines the likelihood of an adve...
|
|
WO/2020/189000A1 |
Problem: to provide a composition for treating renal cell carcinoma and to provide a composition or method for enhancing drug uptake by renal cell carcinoma cells. Constitution: a composition for treating renal cell carcinoma, the compos...
|
|
WO/2020/190890A1 |
Disclosed herein are pyridyl compounds. Also described are specific conjugated nicorandil compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the pyridyl compounds are disclosed for the ...
|
|
WO/2020/188505A1 |
The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of 75 mg of vibegron per day.
|
|
WO/2020/187123A1 |
Disclosed are a pyrrole amidopyridone represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereomer, a tautomer, a solvate, a polymorph, or a prodrug thereof, a preparation method there...
|
|
WO/2020/184700A1 |
Provided are a nucleic acid complex and a method for lowering the expression of IHH gene mRNA and protein in an animal. The nucleic acid complex for lowering the expression of IHH gene mRNA and protein acts as a specific inhibitor of t...
|
|
WO/2020/183456A1 |
The present invention is directed to a cannabinoid combination comprising, as the only cannabinoids, cannabidiol (CBD) and A9-tetrahydrocannabinol (THC), or enantiomers, diastereomers, or racemates thereof, for use in the treatment of ch...
|
|
WO/2020/184691A1 |
A drug containing a compound represented by formula (I) as an active ingredient, used for complications from diabetes.
|
|
WO/2020/186187A1 |
Methods of treating bladder or urethra dysfunction or disease in a subject and methods of increasing bladder smooth muscle contractility or increasing bladder wall volume in a subject are disclosed. In some examples, a purine nucleoside ...
|
|
WO/2020/182870A1 |
The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful...
|
|
WO/2020/186154A1 |
Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A a...
|
|
WO/2020/178847A1 |
"Co-crystal of Roxadustat" The present invention relates to D-proline Co-crystal of Roxadustat having improved stability and suitable for commercial development. The invention also relates to process for the preparation of D- proline Co-...
|
|
WO/2020/177094A1 |
Provided in the present invention is the use of methyl myristoleate in the preparation of products for preventing and/or treating metabolic syndrome or improving body energy metabolism, wherein the products are medicines, foods or health...
|
|
WO/2020/177729A1 |
The present invention relates to a fused aromatic ring derivative, a preparation method therefor, and a pharmaceutical application thereof. In particular, the present invention relates to a fused aromatic ring derivative represented by g...
|
|
WO/2020/179571A1 |
Provided is a method for inhibiting myostatin signal. The following protein (a) or (b). (a) A protein which comprises the following amino acid sequence. (b) A protein which comprises an amino acid sequence having at least 70% sequence id...
|
|
WO/2020/173476A1 |
A pharmaceutical composition containing a renal outer medullary K channel inhibitor and a preparation method therefor. The pharmaceutical composition contains (R)-5-cyano-N-(1-(2-hydroxy-2-(4-methyl-1-carbonyl-1,3-dihyd
roisobenzofuran-5...
|
|
WO/2020/175597A1 |
Provided is a medicinal composition to be used for preventing and/or treating tissue fibrotic diseases. The medicinal composition according to the present invention, which comprises a PI3Kδ inhibitor as an active ingredient, exhibits ex...
|
|
WO/2020/176470A1 |
Provided is a method of treating benign prostatic hyperplasia (BPH) in a patient. Also provided is a method of inhibiting non- adrenergic contraction of a smooth muscle. Additionally provided is a method of inhibiting proliferation of hu...
|
|
WO/2020/176894A1 |
The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to con...
|
|
WO/2020/169783A1 |
Methods of treating and preventing kidney injury through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.
|
